Brain and Cognitive Changes After Reasoning Training in Individuals With Mild Cognitive Impairment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02596906 |
Recruitment Status :
Completed
First Posted : November 4, 2015
Results First Posted : December 11, 2020
Last Update Posted : January 7, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Mild Cognitive Impairment | Device: tDCS Device: Sham tDCS | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 22 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Brain and Cognitive Changes After Reasoning Training in Individuals With Cognitive Complaints |
Study Start Date : | January 2016 |
Actual Primary Completion Date : | January 2018 |
Actual Study Completion Date : | January 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: tDCS+Training
This group will receive 20 minutes of tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks
|
Device: tDCS
Prior to the reasoning training, participants will undergo tDCS. Participants will receive 20 minutes of tDCS using 2mA or less targeting the inferior frontal gyrus prior to each of their 8 reasoning training sessions for a total of 160 total combined minutes. This time does not include set up time which should take no more than 5 minutes. A brief engaging film is shown to participants during the 20 minute session. |
Sham Comparator: Sham tDCS+training
This group will receive 20 minutes of "sham" tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks.
|
Device: Sham tDCS
For the sham tDCS group, the device will be turned off after 30s. The only reported sensations from tDCS is an itching or a tingling when the device turns on but disappears quickly. Thus, those receiving sham tDCS will be unaware that the device has turned off, and will experience an initial tingling similar to that received in the tDCS group. |
- Change From Baseline in California Verbal Learning Task Score [ Time Frame: Baseline to 4 weeks and 3 months post-training ]
To examine short-term and long-term effects of treatment on cognition and real-life outcomes. The participant will undergo neuropsychological testing at baseline, post-training (4 weeks), as well as 3-months post-training.
Scores on the scale range from 0 to 16 on the California Verbal Learning Task. Higher the values are better their memory.
- Regional Brain Blood Flow Change Immediately After 1 Month of Cognitive Training and tDCS Brain Stimulation [ Time Frame: Two longitudinal measurements at baseline and 1-month ]Non-invasive estimation of rCBF by perfusion maps using pseudo-continuous arterial spin labeling (pCASL) MRI. rCBF is quantified as mL/min/100g tissue.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Safely have an MRI
- Cognitive complaints in the absence of dementia
- Participate in tasks involving motor abilities such as use of at least one arm and hand
- Read, speak, and comprehend English
- 50-80 years of age
- Comprehend simple instructions, perform tasks, and take part in intervention
Exclusion Criteria:
- Not proficient in reading, comprehending, or speaking English
- Individuals who have any significant health, neurological, or psychiatric illness, or history of substance abuse
- Individuals with any MR contraindications (i.e., non-removable metal within/on the body)
- Individuals taking medications which are contraindicatory for the tDCS procedure
- Individuals who are left-handed
- Not proficient in reading,comprehending, and speaking English
- Females who are not post-menopausal
- Pre-existing cerebral palsy, autism, epilepsy, schizophrenia, pervasive developmental disorder, thyroid diseases, diabetes, claustrophobia, non-correctable vision problems, major depression, psychosis, active behavioral disorder, or uncontrolled epilepsy.
- Women who are pregnant

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02596906
United States, Texas | |
UTD Center for BrainHealth | |
Dallas, Texas, United States, 75235 |
Principal Investigator: | Sandra Chapman, PhD | The University of Texas at Dallas |
Documents provided by Sandra Chapman, PhD, The University of Texas at Dallas:
Responsible Party: | Sandra Chapman, PhD, Director, Center for BrainHealth, The University of Texas at Dallas |
ClinicalTrials.gov Identifier: | NCT02596906 |
Other Study ID Numbers: |
CBH-MCI-tDCS |
First Posted: | November 4, 2015 Key Record Dates |
Results First Posted: | December 11, 2020 |
Last Update Posted: | January 7, 2021 |
Last Verified: | December 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Cognitive Dysfunction Cognition Disorders Neurocognitive Disorders Mental Disorders |